Processa Pharmaceuticals Inc Stock Price, News & Analysis

Processa Pharmaceuticals (PCSA) has entered into a binding term sheet with Intact Therapeutics for an exclusive option to license PCS12852, a 5-HT4 receptor agonist targeting gastroparesis treatment. The deal includes $452.5M in total milestone payments, comprising a $2.5M option exercise fee, up to $20M in development/regulatory milestones, and $432.5M in commercial milestones. Intact will pay double-digit royalties on worldwide net sales (excluding South Korea) and provide Processa with a 3.5% equity stake. PCS12852, which completed Phase 2a trials showing strong safety and efficacy in diabetic gastroparesis patients, aims to restore normal gastric emptying without cardiovascular and CNS side effects. Processa must share 60% of cash payments with its licensor, excluding the equity stake. The agreement allows Processa to focus on oncology while monetizing non-oncology assets.

Processa Pharmaceuticals (NASDAQ: PCSA) announced its participation in the 2025 BIO International Convention in Boston from June 16-19, 2025. CEO Georg Ng and President R&D Dr. David Young will conduct one-on-one meetings with potential partners and investors to discuss the company's strategic direction and clinical developments. The meetings will focus on their Next Generation Cancer (NGC) platform, particularly their lead asset NGC-Cap, which is in Phase 2 trials for metastatic breast cancer. The BIO International Convention is the biotechnology industry's largest gathering, attracting over 20,000 global leaders for networking and collaboration opportunities.

Processa Pharmaceuticals announced the acceptance of three abstracts for presentation at the 2025 ASCO Annual Meeting. The presentations focus on their Next Generation Cancer drug candidates PCS6422 and PCS11T. The main presentation features their Phase 2 adaptive design trial of PCS6422 (eniluracil) combined with capecitabine for advanced/metastatic breast cancer. Two additional online-only abstracts cover: (1) Phase 1b trial results defining MTD and RP2DR for NGC-Cap, showing improved safety and anti-tumor activity, and (2) preclinical Project Optimus dose escalation study of PCS11T, a tumor-targeted SN-38 pro-drug designed to increase tumor drug concentration while reducing systemic toxicity.

Processa Pharmaceuticals (Nasdaq: PCSA) has announced that Dr. David Young, Founder and President of Research & Development, will present at the World Orphan Drug Congress USA 2025 in Boston. The presentation, scheduled for April 24, 2025, at 2:00 p.m. ET, will focus on 'Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases'.

Dr. Young will discuss how Project Optimus principles can be utilized to determine optimal dosing for improved efficacy and safety in rare disease treatments, both oncological and non-oncological. This approach aligns with Processa's Regulatory Science strategy, which aims to enhance therapeutic outcomes through improved regulatory science methodologies.

Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company specializing in next-generation cancer therapies, has announced its participation in the upcoming MedInvest Biotech and Pharma Investor Conference. The event will take place on March 27-28, 2025, at Cooley's law office in New York City.

The company's management team will deliver a corporate overview presentation on March 28th at 9:40 a.m. Eastern time. Additionally, they will engage in one-on-one meetings with registered investors and conference attendees throughout the event. The presentation materials will be made accessible on Processa's website.

Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, has announced its participation in the 2025 BIO CEO & Investor Conference. The event will take place on February 10-11, 2025, at the New York Marriott Marquis.

The company's management will deliver a corporate overview presentation on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room. Throughout the conference, management will be available for one-on-one meetings with registered investors and attendees. Interested parties can schedule meetings through the BIO Partnering portal, while those unable to attend can contact Yvonne Briggs at Alliance Advisors to arrange meetings with management.

Processa Pharmaceuticals (PCSA) has completed its previously announced public offering, raising $5 million in gross proceeds. The offering included 8,050,672 shares of common stock (or pre-funded warrants) with accompanying Series A warrants to purchase up to 8,050,672 shares and Series B warrants for up to 4,025,336 shares.

The offering price was set at $0.615 per share for institutional investors and $0.7975 for the Company's CEO and board members. Notable participants included the Company's CEO, board members, existing institutional investors, and a healthcare-focused institutional investor. A.G.P./Alliance Global Partners served as the sole placement agent for the offering, which was conducted under a Form S-1 registration statement declared effective on January 27, 2025.

Processa Pharmaceuticals (PCSA) has announced the pricing of a $5 million public offering, featuring 8,050,672 shares of common stock with accompanying warrants. The offering includes participation from the company's CEO, board members, existing institutional investors, and a healthcare-focused institutional investor.

The offering is priced at $0.615 per share for institutional investors and $0.7975 for company insiders, with both Series A and Series B warrants included. Series A warrants allow purchase of up to 8,050,672 shares at $0.65 per share with a five-year term, while Series B warrants cover 4,025,336 shares at $0.65 per share with an eighteen-month term.

The closing is expected around January 29, 2025, with A.G.P./Alliance Global Partners acting as sole placement agent. The company must seek stockholder approval within 90 days for the issuance of shares upon warrant exercise.

Processa Pharmaceuticals reports progress in its oncology pipeline and Q3 2024 financial results. The company has dosed its first patient in a Phase 2 trial of NGC-Cap for metastatic breast cancer, with interim data expected in H2 2025. Preclinical studies for NGC-Iri showed improved tumor targeting compared to irinotecan and Onivyde®. Financial highlights include R&D expenses of $2.3M (up from $1.2M in Q3 2023), G&A expenses of $1.1M, and a net loss of $3.4M ($1.03 per share). Cash position stands at $2.9M as of September 30, 2024.